Skip to main content

Table 5 Multiparametric tumor marker analysis in colorectal cancer.

From: Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer

  Colorectal cancer
  Sensitivity Specificity
Two markers Both positive Either positive Both negative Either negative
PAI-1 + CATB 78% 98% 73% 98%
PAI-1 + uPA 64% 98% 67% 98%
PAI-1 + CATL 39% 96% 67% 96%
CATB + uPA 55% 95% 79% 87%
CATB + CATL 41% 84% 75% 94%
CATL + uPA 30% 80% 72% 90%
PAI-1 + CEA 30% 96% 73% 98%
CATB + CEA 28% 84% 83% 95%
uPA + CEA 20% 80% 76% 95%
CATL + CEA 20% 52% 75% 94%
PAI-1 + CA 19-9 18% 96% 77% 98%
CATB + CA 19-9 16% 84% 86% 97%
uPA + CA 19-9 14% 73% 80% 95%
CATL + CA 19-9 11% 48% 78% 95%
CEA + CA 19-9 16% 32% 86% 97%
Three markers All positive Either positive All negative Either negative
PAI-1 +CEA +CA 19-9 16% 96% 71% 98%
CATB +CEA +CA 19-9 14% 84% 80% 97%
uPA +CEA +CA 19-9 12% 80% 74% 97%
CATL +CEA +CA 19-9 9% 52% 74% 97%
  1. Sensitivity and specificity values of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 during multiparametric tumor marker analysis in colorectal cancer (n = 56)
  2. CATB: cathepsin B; CATL: cathepsin L; uPA: urokinase-type plasminogen activator, PAI-1: plasminogen activator inhibitor type-1; CEA: carcinoembryonic antigen; CA 19-9: carbohydrate antigen 19-9;
  3. Both: both markers correctly positive or negative; All: all three markers correctly positive or negative; Either: one of two/or three markers correctly positive or negative